A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).
Selina M. Luger
Research Funding - MethylGene
Casey Lee O'Connell
Research Funding - MethylGene
Virginia Klimek
Research Funding - MethylGene
Maureen A. Cooper
Research Funding - MethylGene
Emmanuel C. Besa
Research Funding - MethylGene
James M. Rossetti
Research Funding - MethylGene
Gregory K. Reid
Employment or Leadership Position - MethylGene
Rachel Humphrey
Employment or Leadership Position - MethylGene
Stock Ownership - MethylGene
Robert E. Martell
Stock Ownership - MethylGene
Research Funding - MethylGene
Guillermo Garcia-Manero
Research Funding - MethylGene